全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Jens-Otto Andreas , Marina Braun
来源:[J].Clinical Therapeutics(IF 2.23), 2015, Vol.37 (4), pp.902-912Elsevier
摘要:Abstract(#br)Purpose(#br)Rotigotine, a nonergolinic dopamine receptor agonist, is a once-daily transdermal patch developed for the treatment of Parkinson’s disease and restless legs syndrome. The objective of the present study was to determine the pharmacokinetic characteris...
作者:Jens-Otto Andreas , Francois-Xavier Mathy
来源:[J].Drugs(IF 4.633), 2015, Vol.75 (5), pp.487-501Springer
摘要:Abstract(#br)This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D3/D2/D1 dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson’s disease (PD...
作者:Jens-Otto Andreas , Michelle Middle
来源:[J].Clinical Therapeutics(IF 2.23), 2012, Vol.34 (4), pp.966-978Elsevier
摘要:Abstract(#br)Background(#br)The dopamine agonist rotigotine is formulated in a transdermal delivery system (patch) for once-daily application. It has been reported as efficacious in the treatment of idiopathic Parkinson's disease (PD) and restless legs syndrome.(#br)Objectiv...
作者:Willi Cawello , Marina Braun , Jens-Otto Andreas
来源:[J].European Journal of Drug Metabolism and Pharmacokinetics(IF 0.944), 2018, Vol.43 (4), pp.475-481Springer
摘要:Abstract(#br) Background and Objective(#br)Pharmacokinetic studies using deconvolution methods and non-compartmental analysis to model clinical absorption of drugs are not well represented in the literature. The purpose of this research was (1) to define the system of equati...
作者:... Katsumi Yamamoto , Katsumi Yoshida , Jens-Otto Andreas
来源:[J].European Journal of Drug Metabolism and Pharmacokinetics(IF 0.944), 2015, Vol.40 (4), pp.461-469Springer
摘要:Abstract(#br)The intravenous (iv) formulation of levetiracetam has been available in clinical practice worldwide for several years, but not in Japan. Two open-label studies were conducted: Study A evaluated the bioequivalence of iv and oral tablet formulations in healthy Jap...
作者:Willi Cawello , Christa Mueller-Voessing , Jens-Otto Andreas
来源:[J].Clinical Drug Investigation(IF 1.915), 2014, Vol.34 (5), pp.327-334Springer
摘要:Abstract(#br) Background(#br)Recent data suggest that P-glycoprotein may be involved in cellular transport of lacosamide.(#br) Objective(#br)To investigate potential drug–drug interactions (DDIs) between lacosamide and digoxin, this phase I, multiple-dose, randomised, double...
作者:Hans P Zahradnik , Jutta Goldberg , Jens-Otto Andreas
来源:[J].Contraception(IF 3.09), 1998, Vol.57 (2), pp.103-109Elsevier
摘要:Abstract(#br)The aim of this open, noncontrolled phase III study was the assessment of the contraceptive efficacy and the evaluation of the safety of long-term use of Belara® (30 μg ethinyl estradiol plus 2 mg chlormadinone acetate). Furthermore, cycle stability during admin...
作者:Jens-Otto Andreas , Klaus Linz
来源:[J].European Journal of Pharmacology(IF 2.592), 2005, Vol.512 (1), pp.53-60Elsevier
摘要:Abstract(#br)The effects of drugs that inhibit human ether-a-go-go-related gene (HERG) related cardiac potassium channels on the variability of QT duration as a sign of repolarisation instability were evaluated in conscious telemetered dogs. QT duration variability was deter...
作者:Jens-Otto Andreas , Pamela Doty ...
来源:[J].Journal of Clinical Psychopharmacology(IF 3.513), 2017Wolters Kluwer
摘要:PURPOSE: This phase 1, randomized, double-blind, placebo- and active comparator–controlled crossover study assessed the abuse potential of the antiepileptic drug, lacosamide. METHODS: After a qualification phase, 38 healthy, recreational central nervous system–depressant use...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×